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ABSTRACT: Drug-induced proarrhythmicity is a major
concern for regulators and pharmaceutical companies. For
novel drug candidates, the standard assessment involves the
evaluation of the potassium hERG channels block and the in
vivo prolongation of the QT interval. However, this method is
known to be too restrictive and to stop the development of
potentially valuable therapeutic drugs. The aim of this work is
to create an in silico tool for early detection of drug-induced
proarrhythmic risk. The system is based on simulations of how
diﬀerent compounds aﬀect the action potential duration
(APD) of isolated endocardial, midmyocardial, and epicardial cells as well as the QT prolongation in a virtual tissue. Multiple
channel−drug interactions and state-of-the-art human ventricular action potential models (O’Hara, T., et al. PLos Comput. Biol.
2011, 7, e1002061) were used in our simulations. Speciﬁcally, 206.766 cellular and 7072 tissue simulations were performed by
blocking the slow and the fast components of the delayed rectiﬁer current (IKs and IKr, respectively) and the L-type calcium
current (ICaL) at diﬀerent levels. The performance of our system was validated by classifying the proarrhythmic risk of 84
compounds, 40 of which present torsadogenic properties. On the basis of these results, we propose the use of a new index (Tx)
for discriminating torsadogenic compounds, deﬁned as the ratio of the drug concentrations producing 10% prolongation of the
cellular endocardial, midmyocardial, and epicardial APDs and the QT interval, over the maximum eﬀective free therapeutic
plasma concentration (EFTPC). Our results show that the Tx index outperforms standard methods for early identiﬁcation of
torsadogenic compounds. Indeed, for the analyzed compounds, the Tx tests accuracy was in the range of 87−88% compared with
a 73% accuracy of the hERG IC50 based test.
1. INTRODUCTION
Preclinical assessment of cardiac adverse eﬀects for drug
candidates has become a priority for regulatory agencies and
pharmaceutical companies due to the occurrence of potentially
life-threatening ventricular arrhythmias following the admin-
istration of drugs.1−5 Nowadays, cardiac safety tests of
pharmacological compounds are mainly based on the observed
in vitro block of the human ether-a-̀go-go-related gene, hERG,
current (encoding the pore-forming α-subunit of the rapid
component of delayed rectiﬁer current (IKr) channels in
humans) produced by the compound, and the in vivo
prolongation of the QT interval (ICH S7B nonclinical
guidance6 and E14 clinical guidance7).
Indeed, many studies have revealed that block of IKr
promotes the drug-induced long QT syndrome, associated
with increased proarrhythmic risk.8 Prolongation of the QT
interval has traditionally been linked to the initiation of torsade
de pointes (TdP) in the clinical practice. However, there are
hERG blockers that do not lead to TdP such as verapamil.9,10
Although current guidelines6,7 have been successful in
preventing proarrhythmic eﬀects of drugs, the limitations of
these criteria have contributed to stop the development of
potentially valuable compounds. A more accurate prediction of
unwanted eﬀects of drug candidates at early stages of drug
development is key for safety pharmacology.11
In the last years, diﬀerent modeling techniques have been
employed in order to improve the prediction of side eﬀects of
compounds. Biophysically detailed mathematical models of
cardiac electrical activity12−16 and statistical models9,17−19 have
been used in these studies. Additionally, the work of Lancaster
and Sobie20 combines both types of models. A nice comparison
of diﬀerent classiﬁcation schemes can be found in a recent
review of Wisniowska and Polak.21 The use of modeling and
simulation tools of the cardiac electrophysiological activity to
predict the proarrhythmic risk of drugs is currently being
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considered by diﬀerent international initiatives such as the
comprehensive in vitro pro-arrhythmia assay (CiPA).22
Recent studies suggest that prediction of arrhythmogenicity
could be improved by considering the eﬀects of drugs on
multiple ion channels,9,12,13,16 the therapeutic plasma drug
concentrations,23,24 and the use of biophysically detailed
mathematical models of cardiac electrical activity.25−29
In a previous work,13 we introduced a multiscale simulation
system to predict drug-induced cardiotoxicity by considering
the eﬀects of drugs in two main transmembrane ionic currents:
IKr and the slow component of the delayed rectiﬁer current
(IKs). Here, we create an in silico tool for early detection of
drug-induced proarrhythmic risk that provides a new index
called Tx, which summarizes in a single parameter the block of
diﬀerent channels in the context of the relevant drug
concentration. Action potential duration (APD) and QT
prolongations were simulated using the state-of-the-art human
ventricular action potential model (O’Hara et al. model30) and
taking into account the eﬀect of the block of three
transmembrane ionic currents: fast and slow components of
the potassium delayed current (IKr and IKs) and L-type calcium
current (ICaL). The simulations have been run over a wide range
of concentrations and block values for these currents thus
precomputing the cardiac eﬀect that most drug candidates
could produce.
The system was used to perform a retrospective cardiac
safety study of 84 compounds, 40 of which present
torsadogenic properties, according to the information provided
by CredibleMeds.31 Our results reveal that the Tx index could
be a much better predictor of the torsadogenic risk than criteria
based solely on the concentration for 50% hERG inhibition
(hERG IC50). Therefore, assessment of drug-induced proar-
rhythmicity of a compound could be improved by using the Tx
index based on in silico APD and QT prolongation methods.
Indeed, knowing the IC50s for IKr, IKs, and ICaL of a compound,
our method can be applied to obtain an estimate of the
maximum safe plasma free concentration.
Table 1. Characteristics of the 84 Drugs Used in This Study: Name (First Column), Torsadogenic Risk (Second Column and
Color-Coded Background of the First Column: Red (Class 1), Orange (Class 2), Bright-Green (Class 3) and Dark-Green (Class
4)), pIC50 (−log IC50) Values for hERG, IKs, and ICaL (Third to Fifth column) and the EFTPC (Sixth Column)
a
aReferences for all the values in this table are given in the Supporting Information (Table S1).
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2. METHODS
2.1. Cellular and Tissue in Silico Simulations. The
action potential (AP) of human ventricular cells was simulated
using the human ventricular AP model proposed by O’Hara et
al. (ORd30). The block of IKr, IKs, and ICaL provoked by a drug
concentration (D) on the ionic current (i) was simulated by
including the fraction of unblocked channels (1 − bi) in their
formulations and was calculated using the standard sigmoid
dose−response curve (eq 1), parametrized using the half-
maximal response dose for each current (IC50,i) and considering
a Hill coeﬃcient of 1, as in previous studies:12,13,16,20
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The eﬀects of drugs on IKr (hERG), IKs (KCNQ1), and ICaL
(Cav1.2) currents have been analyzed in previous simulation
studies using this simple pore block model.11−13,19,32,33 APDs
were sampled at 90% repolarization (APD90) in isolated
epicardial, midmyocardial, and endocardial myocytes at 1 Hz,
while pseudo-ECGs were computed using a one-dimensional
(1D) tissue model of a transmural wedge preparation. The 1D
model was composed by 60 endocardial cells, 45 midmyo-
cardial cells, and 60 epicardial cells30 (100 μm long each cell),
as deﬁned in the ORd model. Models were paced at 1 Hz, as
this frequency is widely used in simulations of the human
cardiac electrical activity performed to predict the proar-
rhythmic risk of drugs.12,16,20,28,34 The stimulation train of
square transmembrane current pulses of 0.5 ms duration and
1.5-fold the diastolic threshold was delivered at the isolated
cells and at the endocardial end of the 1D model. The
propagation of the AP was described by the following nonlinear
reaction diﬀusion eq (eq 2):
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where Cm is the membrane capacitance, a stands for the radius
of the ﬁber, ∑ Iion represents the sum of all the ionic currents
ﬂowing through the cellular membrane, and Ri is the
intracellular resistivity.
Isolated epicardial, midmyocardial, and endocardial cellular
models were paced with 1000 pulses at 1 Hz in order to achieve
the steady state in control. The steady state of the 1D model in
control conditions was reached by applying a train of 100
pulses at 1 Hz, the initial conditions for each cell type being the
steady state variables obtained from the previously stabilized
isolated cellular models. To reach the steady state under drug
exposure, the fraction of unblocked channels was introduced in
the models, and they were paced for 100 additional pulses (1
Hz). For both cellular and 1D models, the results used in our
study correspond to the 100th pulse of the last stimulation
period.
The QT interval in the pseudo-ECG was computed as the
interval between the onset of the QRS complex and the point
where the end of the T wave reached the baseline. The pseudo-
ECG was measured at 2 cm from the epicardial end. Fifteen
cells from both ends of the ﬁber were excluded from the
gradient measurement to eliminate boundary eﬀects.30
2.2. Drug Data Set. The proarrhythmic risk of 84
compounds (see Table 1) was assessed using our in silico
APD90 and QT prolongation assays. For these drugs, clinical
human torsadogenic risk classiﬁcation was taken from
CredibleMeds, which is on the current AZCERT’s Web
site,31 deﬁning the following categories: class 1, compounds
with risk of TdP; class 2, compounds with possible risk of TdP;
class 3, compounds with conditional risk of TdP; and class 4,
drugs that should be avoided by patients with congenital LQTS.
We deﬁned the 40 class 1 and 2 compounds as torsadogenic
due to their ability to produce TdP on their own, while the 44
class 3 and 4 compounds were deﬁned as nontorsadogenic as
they require speciﬁc interactions to produce TdP. According to
Mirams et al.,12 ajmaline was included in class 1. Drugs for
which no evidence of TdP was found in CredibleMeds were
also included in class 4. IC50 values for IKr, IKs, and ICaL and
EFTPC values were obtained from public databases, like
DailyMed, PubChem, and DrugBank, when available. Other-
wise, the values were taken from the scientiﬁc literature.
EFTPC values were used either directly from the source or
Figure 1. Simulated time course of the action potential of isolated endocardial (Endo), midmyocardial (Mid), and epicardial (Epi) cells (from left to
right) under control conditions and in the presence of bepridil (33 nM) and nifedipine (32.3 nM) (from top to bottom). Vertical lines in each panel
correspond to 10% prolongation of the control APD90 (APD90CNT).
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calculated from peak plasma concentrations derived from the
administration of the drug alone (see Supporting Information,
Table S1). We consistently selected the worst-case scenario by
searching for the highest dosage regimen proposed by the
labels. IC50 values registered in mammalian tissues have been
selected when available, avoiding those extracted from Xenopus
oocytes. Median values were used when multiple IC50 values
were presented. Dashed IC50 boxes mean that no value was
found in public databases either in the scientiﬁc literature for
these compounds. In those cases, our simulations assume no
block of the corresponding channel.
3. RESULTS
3.1. APD and QT. The eﬀect of the 84 selected drugs on the
endocardial, midmyocardial, and epicardial APD90 was
simulated using the pIC50 values for hERG, IKs, and ICaL and
the EFTPC for each compound (see all detailed results in the
Supporting Information, Table S2). Figure 1 illustrates some
examples of the simulated APs of isolated cells (from left to
right) under control conditions and in the presence of bepridil
([D] = EFTPC = 33 nM) and nifedipine ([D] = EFTPC = 32.3
nM) (from top to bottom). Vertical lines in each panel
correspond to 10% APD90 prolongation. Simulated endocardial,
midmyocardial, and epicardial control APD90s are 266.4, 330.3,
and 223.8 ms, respectively. This ﬁgure shows that the APD90 is
markedly prolonged under exposure to the EFTPC of the
torsadogenic compound bepridil (APD90s are 331.1, 398.0, and
278.0 ms, and APD90 increments are 24.3%, 20.5%, and 24.2%,
respectively). On the contrary, APD90 is reduced under
exposure to the EFTPC of the nontorsadogenic compound
nifedipine (endocardial, midmyocardial, and epicardial APD90s
are 236,6, 315.7, and 216.1 ms, and APD90 increments are
−11.2%, −4.4%, and −3.4%, respectively).
As the QT interval prolongation is used in the assessment of
drug proarrhythmic risks, the eﬀects of the 84 compounds on
the QT interval was also simulated (see Supporting
Information, Table S2). Figure 2 depicts the virtual one-
dimensional transmural tissue (top panel) and the simulated
pseudo-ECG at 2 cm from the epicardial end, for control, and
for bepridil and nifedipine at their respective EFTPC (second
to bottom panel). Simulated control QT interval (QTCNT) is
313 ms. Vertical lines in each panel correspond to 10%
prolongation of the QTCNT.
13 The QT interval is markedly
prolonged under exposure to the EFTPC of bepridil (QT
interval = 376 ms and QT interval increment = 20.1%), while it
is reduced under exposure to the EFTPC of nifedipine (QT
interval = 299 ms and QT interval increment = −4.5%). The
eﬀects of these two drugs on the QT interval are in agreement
with those obtained in the APD90s of isolated cells (Figure 1).
To facilitate the prediction of the potential proarrhythmic
risk of a wide range of drugs without carrying out a time-
consuming simulation, the eﬀect on the simulated action
potential durations of the three types of myocardial cells and of
QT intervals were precomputed for a large number of IKr, IKs,
and ICaL block values and concentration combinations. The
206.766 simulations of the electrical activity of isolated
myocytes were run at a pacing rate of 1 Hz, varying the ratios
of drug concentration over the IC50 of each considered ion
channel (IKr, IKs, and ICaL), ranging from 10
−3 to 101 with a 100.1
step increment. 7072 simulations were performed to obtain the
QT intervals at 1 Hz. In this case, the ratios of drug
concentration over the IC50 ranged from 10
−2 to 101 for IKr
and IKs and from 10
−2 to 100 for ICaL. Additionally, step
increments depended on the ion channel. Speciﬁcally, IKr step
increment was set to 100.2 except for the ratios between 10−1.2
and 10−0.2, where it was set to 100.1, and IKs and ICaL step
increments were set to 100.25 and 100.2, respectively.
Figure 3 shows a 3D representation of the surface (blue
striped) corresponding to the 110% of control APD90 (110%
CNT) for endocardial (top left), midmyocardial (top right),
and epicardial (bottom left) cells as well as the QT interval
(bottom right). Coordinate axes represent the logarithm of the
ratio of the drug concentration (D) over the IC50 of each
channel, which expresses how much larger the concentration
used in the simulation is than the concentration known to block
50% of channels. IKr and IKs block increases APD90s and the QT
interval, while ICaL block decreases them, so the back bottom
left zones of the blue surface correspond to APD90s and QT
intervals longer than 110% of control values while front top
right zones correspond to APD90s and QT intervals shorter
than 110% of control values. Those compounds that fall left to
the 110% blue surfaces prolong the APD90 or the QT interval
more than 10%, like disopyramide (red triangle) and bepridil
(red cube) at EFTPC. Conversely, those compounds that fall
right of the 110% blue surfaces prolong the APD90 or QT less
than 10%, like nontorsadogenic drugs raltegravir (green circle)
and phenytoin (green cube), at EFTPC.
Figure 2. Representation of the virtual transmural 1D tissue (top
panel) and the time course of the pseudo-ECG for control and for
bepridil and nifedipine at their therapeutic concentrations (second to
bottom panel), respectively. Black vertical lines in each panel
correspond to 10% prolongation of the control QT interval
(QTCNT), whose measurement is shown in red.
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It is possible to observe how the surfaces representing the
110% of control of the endocardial and epicardial APD90 and of
the QT interval are quite similar, while the midmyocardial
APD90 is more sensitive to IKs block. Also, within the computed
limits, IKr block exerts the strongest inﬂuence on APD90 and
QT prolongation among the three channels. Indeed, approx-
imately 9% of IKr channels (log([D]/IC50−IKr) = −1) should be
blocked in order to reach the 110% of the endocardial APD90
and the QT interval. However, when ICaL is inhibited, the
percentage of blocked IKr channels needed to prolong the 10%
of the APD90 and the QT interval increases. For example, for
50% of ICaL inhibition (log([D]/IC50−ICaL = 0)), the percentage
of IKr block reaches 24%, with no block of IKs (log([D]/IC50−IKs
= −3)).
3.3. New Indices for TdP Risk Assessment. Figure 4
represents the relationship between the pIC50 hERG values
(−log IC50 hERG) and the risk classiﬁcation for the 84 drugs,
40 torsadogenic and 44 nontorsadogenic drugs (positive
response pIC50 > 6). This ﬁgure shows that 39 out of the 44
nontorsadogenic compounds (class 4 (dark-green) and class 3
(bright-green) compounds) have pIC50 hERG values smaller
than 6 (vertical black line), and their nontorsadogenic risk
would be well predicted by this criterion, while 5 out of those
44 would be misclassiﬁed as positives. Conversely, 18 out of the
40 torsadogenic drugs (class 1 (red) and class 2 (orange)) have
pIC50 hERG values smaller than 6, resulting in false negatives.
The performance of this test is described by the confusion
matrix included in Figure 4B. The performance for the decision
pIC50 hERG > 6 was: sensitivity (true positive rate) of 55%,
speciﬁcity (true negative rate) of 89%, and accuracy (true rate)
of 73%.
To summarize the block of the diﬀerent channels in the
range of the relevant drug concentration in a single parameter,
we deﬁne the new index, Tx, as the ratio of drug concentrations
leading to a 10% prolongation of the APD90 or QT ([D10])
over the maximum eﬀective free therapeutic plasma concen-
Figure 3. 3D representation of the surface (blue striped) corresponding to the 110% of the control endocardial (top left), midmyocardial (top right),
and epicardial (bottom left) APD90 and QT interval (bottom right) together with selected torsadogenic drugs, namely disopyramide (red triangle),
bepridil (red cube), and nontorsadogenic drugs, namely raltegravir (green circle) and phenytoin (green cube). Coordinate axes represent the
logarithm of the ratio of the drug concentration over the IC50 of each channel (log([D]/IC50)).
Figure 4. (A) Relationship between the pIC50 hERG values (−log IC50
hERG) and the color-coded risk classiﬁcation for the 84 drugs used in
this study: class 1 (red) and class 2 (orange), class 3 (bright-green),
and class 4 (dark-green). The vertical line corresponds to pIC50 hERG
= 6. (B) confusion matrix of the pIC50 hERG criterion.
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tration (EFTPC), which is the peak concentration of free
(unbound) drug in blood plasma at maximum therapeutic dose:
=Tx [D ]
EFTPC
10
(3)
This index was quantiﬁed using the following method. The
APD90 and QT at maximum eﬀective free therapeutic
concentration (D = EFTPC) of a certain compound were
looked up in the precomputed matrices (see Figure 3). Then,
the value of log([D]/IC50) for each channel was increased or
reduced by 0.1 if the APD90 or QT was shorter or longer than
110% of control value, respectively, and the APD90 or QT was
evaluated at this new concentration in the matrices. These two
steps were repeated until the 110% of APD90 or QT was
reached, denoting the latter concentration as [D10]. Finally, Tx
was computed as the ratio of [D10] over the maximum
therapeutic concentration (Tx = [D10]/EFTPC). Because of
the resolution of the QT matrix, if a speciﬁc value was not
computed, the closest available value was used instead.
The previously explained method was used to assign a Tx
value to every drug in Table 1 (see Supporting Information,
Table S2). To select the Tx-APD values that best classify drugs
for torsadogenic risk, receiver operating characteristic (ROC)
curves were constructed. Figure 5 shows the ROC curves for
endocardial Tx-APDEndo (green), midmyocardial Tx-APDMid
(black), and epicardial Tx-APDEpi (blue) for increasing decision
thresholds and the optimal cutoﬀ points where sensitivity and
speciﬁcity are maximal (arrows). This ﬁgure illustrates that the
ROC curves are very similar, being the area under these curves
(AUC) of 0.91, 0.90, and 0.90 for the Tx-APDEndo, Tx-APDMid,
and Tx-APDEpi, respectively, which are indicative of overall
concordance. These indicators would therefore provide similar
predictions. The optimal cutoﬀ points of the Tx-APDEndo, Tx-
APDMid, and Tx-APDEpi were 8, 8, and 6.4, respectively. The
ROC curves for the Tx-APDEndo were also generated at 2 and
0.5 Hz. As they are very similar to the Tx-APDEndo ROC curve
at 1 Hz (see Figure S3 in the Supporting Information), we
maintained the frequency at 1 Hz.
Figure 6A represents the obtained Tx-APD (see also
Supporting Information, Table S2), each row containing
compounds belonging to only one CredibleMeds class. Vertical
lines were drawn matching the optimal cutoﬀ values whose
confusion matrices are summarized in Figure 6B. All these tests
led to very similar accuracies (86−87%). However, Tx-APDEndo
and Tx-APDEpi led to 85% sensitivity and 89% speciﬁcity, while
Tx-APDMid led to 85% sensitivity and 86% speciﬁcity.
Similarly, a ROC curve was constructed to study if the index
Tx-QT could improve the prediction of torsadogenic risk
(Figure 7A). Figure 7B shows the relationship between the Tx-
QT and the risk classiﬁcation for the 84 drugs (see also
Supporting Information, Table S2), which resembles the
relationships between the three Tx-APDs and the risk
classiﬁcation for the drugs. The ROC curve for the Tx-QT
shows an area under the curve of 0.90, which is also very similar
to the Tx-APDs (Figure 5). The arrow represents the Tx-QT
(9.2) that provided optimal overall prediction of the
torsadogenic risk, with 85% sensitivity, 89% speciﬁcity, and
87% accuracy (see confusion matrix in Figure 7C).
Figure 8 shows the torsadogenic risk classiﬁcation of the 84
compounds using three diﬀerent criteria: pIC50 hERG > 6 (top
panel), Tx-APDEndo < 8.0 (middle panel) and Tx-QT < 9.2
(bottom panel). It is worth noting that both Tx indices
misclassiﬁed the same 11 compounds from the 84 included in
the data set, whereas hERG test misclassiﬁed 23 compounds.
Tx indices misclassiﬁed as nontorsadogenic (false negative)
three class 1 compounds (compounds with risk of TdP),
namely cilostazol, donepezil, and dronedarone, and three class
2 compounds (compounds with possible risk of TdP), namely
dasatinib, oﬂoxacin, and saquinavir. Additionally, Tx indices
also misclassiﬁed as torsadogenic (false positive) three class 3
compounds (compounds with conditional risk of TdP), namely
metronidazole, quetiapine, and ranolazine, and two class 4
compounds, namely eltrombopag and lamotrigine.
The predictive power of the Tx indices was assessed by using
a leave-one-out cross-validation procedure. We built 84
diﬀerent data sets (training sets) by removing one drug from
Figure 5. In silico isolated cellular Tx-APD assays. ROC curves for the
Tx-APD and optimal cutoﬀ points where sensitivity and speciﬁcity are
maximal (arrows) for the Tx-APDEndo (green), Tx-APDMid (black),
and Tx-APDEpi (blue) (8, 8, and 6.4, respectively). The area under the
curves (AUC) is also indicated.
Figure 6. In silico isolated cellular Tx-APD assays. (A) Relationship between the Tx-APDEndo, Tx-APDMid, and Tx-APDEpi (triangles, squares, and
circles, respectively) values and the risk classiﬁcation for the drugs: class 1 (red), class 2 (orange), class 3 (bright-green) and class 4 (dark-green). (B)
Confusion matrices for the Tx-APDs. The values of the true positive rate (TPR), true negative rate (TNR), and accuracy (A) are also indicated.
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the total compounds each time. ROC curves for the 84 training
sets were used to estimate the optimal cutoﬀ Tx of each
training sets (not shown). ROC curves for APD of endocardial,
midmyocardial, and epicardial cells and for QT interval present
Figure 7. In silico QT interval Tx assays. (A) ROC curves for the Tx-QT and optimal cutoﬀ points where sensitivity and speciﬁcity are maximal for
the Tx-QT (arrow, 9.2). The area under the curve is also indicated. (B) Relationship between Tx-QT and the risk classiﬁcation for the drugs: class 1
(red), class 2 (orange), class 3 (bright-green), and class 4 (dark-green). (C) Confusion matrix for the Tx-QT. The values of the true positive rates
(TPR), true negative rates (TNR), and accuracies (A) are also indicated.
Figure 8. Torsadogenic risk classiﬁcation of the 84 compounds using pIC50 hERG > 6 (top panel), Tx-Endo < 8.0 (middle panel), and Tx-QT < 9.2
(bottom panel).
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very consistent values, with a cutoﬀ Tx of 7.91 ± 0.32 (mean ±
SD), 6.33 ± 0.18, 6.31 ± 0.00, and 9.10 ± 0.19, a sensitivity of
0.85 ± 0.01, 0.83 ± 0.01, 0.85 ± 0.01, and 0.85 ± 0.01, a
speciﬁcity of 0.89 ± 0.01, 0.89 ± 0.01, 0.89 ± 0.01, and 0.89 ±
0.01, and an area under the curve (AUC) of 0.91, 0.90, 0.90,
and 0.90, respectively. For each training set, the “left-out” drug
was classiﬁed according to its Tx value. At the end of the
procedure, we observed that there was a group of drugs that
were misclassiﬁed for any of the Tx used in each test. Tx-
APDEndo, Tx-APDMid, and Tx-QT, also misclassiﬁed clozapine,
as it is the frontier compound when selecting the optimal cutoﬀ
Tx in every ROC curve. In summary, approximately 14% of the
drugs are misclassiﬁed when any of the Tx indices are used to
predict the torsadogenic risk.
Figure 9 shows a 3D representation of the surface (blue
striped) corresponding to optimal cutoﬀ points in ROC curves
for Tx-APDEndo (top left), Tx-APDMid (top right), and Tx-
APDEpi (bottom left) APD90 and Tx-QT (bottom right)
together with Tx calculated for selected drugs. Tx matrices were
built using the same APD and QT matrices used to generate
Figure 3. Tx matrices were constructed to provide a ready-to-
use tool for Tx assessment for drugs whose IC50s for IKr, IKs,
and ICaL, as well as their target concentration, have been
characterized.
Matrices corresponding to Figures 3 and 9 are available from
the institutional and public repository of the Polytechnic
University of Valencia (RIUNET, http://hdl.handle.net/
10251/90297). Moreover, these matrices were incorporated
in a set of predictive models developed within the framework of
the eTOX project48 and included in the eTOXsys integrated
predictive system.49 The open access version of these models is
made accessible online (http://etoxlab-lqt.upf.edu), allowing
reproduction of the results described here as well as to carry out
the assessment of the proarrhythmic risk for other substances.
In the case of new compounds, as the EFTPC is unknown, Tx
matrices can be used to ﬁnd an estimate of the maximum safe
concentration. For this purpose, an initial concentration must
be provided instead of the EFTPC, together with the IC50s.
The Tx matrix for this set of inputs will provide a certain Tx
value. This Tx value must be compared to the optimal cutoﬀ
value of the model. If it is higher, then, the concentration
should be increased while if it is lower, it should be decreased.
Thus, to ﬁnd a maximum safe concentration, the process must
Figure 9. 3D representation of the surface (blue striped) corresponding to optimal cutoﬀ points in ROC curves for Tx-APDEndo (top left), Tx-
APDMid (top right), and Tx-APDEpi (bottom left) APD90 and Tx-QT (bottom right) together with Tx calculated for selected torsadogenic drugs,
namely disopyramide (red triangle) and bepridil (red cube), and nontorsadogenic drugs, namely raltegravir (green circle) and phenytoin (green
cube). Coordinate axes represent the logarithm of the ratio of the drug concentration over the IC50 of each channel (log([D]/IC50)).
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be repeated for several concentrations until the resulting Tx is
equal to the optimal cutoﬀ value of the model.
4. DISCUSSION
4.1. Main Findings. In this paper, we describe a new tool
for the preclinical assessment torsadogenic risk that provides
better predictions that the current state-of-the-art methodology
based only on hERG block. The torsadogenic risk assessment is
based on a new index, Tx, which integrates the inﬂuence of
relevant factors and is deﬁned as the ratio of the drug
concentration, producing 10% prolongation of the cellular
endocardial, midmyocardial, and epicardial APDs or the QT
interval over the maximum EFTPC. This tool employs a large
number of values of prolongations of the APD90 and QT
interval caused by the multichannel block of three important
ionic membrane currents (IKr, IKs, and ICaL), which are
predicted by computer simulations of the electrophysiological
activity of the cardiac cells. By including these multichannel
eﬀects and the maximum EFTPC, misclassiﬁcations in a group
of 84 compounds using the hERG block criterion were
drastically reduced (more than 50%), from 23 to 11. In our
opinion, adoption of these tools into cardiovascular safety
assessment could speed up and reduce the cost of cardiac safety
screening in the early stages of drug discovery.
4.2. In Silico APD90 and QT Prolongation Assay versus
the hERG Block Test. Standard assessment methodologies
focused on hERG block exhibit a poor performance.22,35
Indeed, when applying the hERG test (positive response:
hERG pIC50 > 6) to the 84 compounds considered in this
work, it exhibited a sensitivity of 55%, a speciﬁcity of 89%, and
an accuracy of 73%, which is in close agreement with previous
studies.9,36 In comparison, the in silico Tx tests described in this
study presented an accuracy of 86%−87%.
In a previous paper, we showed that the prediction of the
TdP risk obtained with the classic hERG block could be
improved by simulating the block of IKr and IKs using a guinea
pig AP model.13 In the same year, Mirams and co-workers
simulated the block of IKr, ICaL, and INa by 31 drugs with
diﬀerent risks of TdP and observed that simulation of the
human ventricular APD at therapeutic concentrations improved
the prediction of Redfern and co-workers.12 Both works were
pioneers in using computer models to introduce the multi-
channel eﬀects of drugs for predicting torsadogenic risks. In a
previous work, Mirams et al.16 also assessed the performance of
the prediction of the thorough QT assay in 34 drugs by using
several ventricular human models, and they showed that the
O’Hara et al. model30 exhibited the best performance (88%
accuracy, 71% sensitivity, and 100% speciﬁcity when consider-
ing a wider range of concentrations). More recently, Lancaster
and Sobie20 have also evaluated arrhythmia risk using diﬀerent
ventricular human models and have obtained better scores with
the O’Hara et al. model (89.5% accuracy, 95.9% sensitivity, and
81.1% speciﬁcity). In that work, they combined multichannel
block simulations of 68 drugs (with a total of 86 cases, as 18 of
these drugs were simulated using two diﬀerent models, each of
them constructed with the data of only one of the two sources
of experimental data used in that paper) with statistical analysis
and machine-learning. They observed that arrhythmia risk is
inﬂuenced by both the action potential and the intracellular
calcium concentrations waveforms.
The better performance of our in silico tool compared to the
hERG test cannot be attributed solely to the consideration of
the multichannel block but also to the use of compound
EFTPC. Indeed, previous works have shown that torsadogenic
risk predictions can be improved by including the estimated
free plasma concentration at therapeutic doses of the
compound and multichannel block eﬀects. In 2003, Redfern
and co-workers observed that a safety factor of 30 of the ratio of
the hERG IC50 over the maximum eﬀective free therapeutic
plasma concentration could provide good torsadogenic risk
prediction for 52 drugs23 (77.4% accuracy, 87.5% sensitivity,
and 68% speciﬁcity). Later, Gintant24 proposed the value 45 for
the safety margin, deﬁned as the ratio of the hERG IC50 over
the mean maximal plasma drug concentrations during thorough
QT) studies. Our work extends their ﬁndings with a larger data
set and the inclusion of the multichannel eﬀects of the
compounds.
All in all, our results show that Tx index is a better predictor
than the hERG pIC50 test (accuracy ≈ 88% compared with
73%, respectively) and that the results of predictions obtained
with the four Tx tests (Tx-APDEndo, Tx-APDMid, and Tx-APDEpi
and Tx-QT) are very similar. Moreover, the accuracy of our
classiﬁcation method (87%) is in line with the scores of the
predictions of recent studies, such as Mirams et al. 2014 (88%),
Lancaster and Sobie 2016 (89.5%), or Kramer et al. (90.9%),
but our study considers a larger number of compounds (84
compared to 34, 68, and 55, respectively).
Our simulations have shown that IKs exerts a small inﬂuence
on APD90 of isolated cells and QT prolongation under regular
conditions. This is in accordance with the small amplitude of
the IKs on isolated myocytes from human left ventricles
37 and
with other simulation results.16,30 Moreover, our results show
that the role of ICaL block on APD90 of isolated cells and on QT
prolongation is relevant although to a lesser extent than IKr
block. These facts suggest that the experimental and in silico
study of the eﬀects of drugs on IKr and ICaL on myocytes
isolated from human ventricles is more relevant than drug
eﬀects on IKs. This result is in agreement with the work of
Kramer and collaborators who observed that the TdP risk
prediction provided by the comparison of the blocking
potencies between IKr and ICaL was drastically better than the
prediction obtained by the hERG assay in 55 drugs9 (90.9%
accuracy, 96.9% sensitivity, and 82.6% speciﬁcity).
Other works have simulated APD90 changes in isolated
endocardial cells of diﬀerent species such as guinea pigs,13
rabbits, dogs, and humans12,16 and QT interval changes in
rabbit15 to predict cardiac safety of torsadogenic drugs. Beattie
et al. showed that in silico simulation of the QT prolongation of
the rabbit left ventricular wedge assay had a good predictive
ability (78% accuracy) of the experimental results of the rabbit
left ventricular wedge assay.15 We selected the most recent
human ventricular AP model for our simulations instead of
models of other species with the aim of obtaining more
accurate predictions of drug proarrhythmicity risk in humans.38
Indeed, comparison between human and other species has
revealed a lack of a transient outward current (Ito) in guinea pig,
a small slow delayed rectiﬁer current (IKs) and TdP
predisposition in rabbit, and a large IKs in guinea pig.
39 Other
studies have shown that human IKs diﬀers from that reported in
guinea pig, and it better resembles the ventricular canine or
rabbit IKs.
37
Our work feeds from the progress achieved by the
aforementioned works, such as the consideration of the
therapeutic concentrations and the multichannel eﬀects, and
the use of the most recent human ventricular action potential
model and goes a step further by providing a tool for prediction
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of the torsadogenic risk that can be used by the pharmaceutical
companies at the early stages of drug development. This tool
can be applied when the IC50s for IKr, IKs, and ICaL of a new
compound are estimated without the need of high performance
hardware or cardiac modeling specialized staﬀ, as the
simulations have been precomputed, allowing for an estimate
of a safe concentration. Moreover, the number of drugs used to
depict the ROC curves is signiﬁcantly higher than the number
of compounds used in most previous works.
The new Tx index has signiﬁcantly reduced the misclassiﬁ-
cation obtained with hERG test, although some false positive
and false negative predictions with hERG tests are also
misclassiﬁed with our Tx index. There are many drug-related
aspects that were not included in our work mainly due to
information unavailability, such as traﬃcking inhibition, the
eﬀects on other pathways, the presence of metabolites, and
higher levels of the compound in the myocardium than in
blood plasma. Although these aspects can also apply to properly
classiﬁed drugs, they could have favored the misclassiﬁcation of
some drugs. For example, it has been reported that donepezil
prolongs QT interval not only by IKr block but also by IKr
traﬃcking inhibition.40 Additionally, QT prolongation by
dasatinib is also partially due to its eﬀects on intracellular
PI3K signaling.41 Cilostazol is a phosphodiesterase 3 (PED3)
inhibitor that induces intracellular cAMP elevation, Ca2+
dynamic unbalance, and early after depolarizations (EADs),42
which could favor TdP. Dronedarone is known to transform
into N-debutyl-dronedarone,43 a metabolite that retains up to
one-third of the parent’s activity. Because both show important
channel blocking eﬀects, not considering dronedarone’s main
metabolite might be the cause of its misclassiﬁcation. As for
saquinavir, it could be related to the presence of higher levels in
myocardium than in blood plasma,44 increasing the odds of
producing adverse eﬀects in this tissue. Finally, other factors
can be related to the misclassiﬁcation of oﬂoxacin, quetiapine,
ranolazine, lamotrigine, and eltrombopag. Although oﬂoxacin
has been classiﬁed as a class 2 compound by CredibleMeds,
rare cases of TdP have been reported in patients receiving
it45,46 and experimental data has shown that oﬂoxacin does not
provoke APD prolongation in rabbit Purkinje ﬁbers,47 which
are cells prone to APD prolongation. In our work, we
performed a large number of simulations to take into account
the block eﬀect if the drugs on the three main channels (IKr, IKs,
and ICaL), but a few drugs in our data set show blocking eﬀects
on the Na+ channels, namely quetiapine, ranolazine, and
lamotrigine. Finally, it is worth noting that eltrombopag showed
high variability of its IC50, and its classiﬁcation was uncertain as
there is a lack of strong evidence for placing it in any QT risk
category.31
This study is also in line with current initiatives aiming to
deﬁne a new paradigm in cardiac safety like comprehensive in
vitro proarrhythmia assay (CiPA),22 where modeling and
simulation of the human cellular ventricular electrophysiology
will play a relevant role in the assessment of the proarrhythmic
risk of drugs.
4.5. Limitations of the Study. One of the values of this
work is the use of a large training series because we consider
that this allows obtaining of a more realistic estimation of the
prediction errors. However, the IKs and ICaL IC50 values of some
compounds were not available from the literature, and it was
assumed that the block of these channels was negligible,
similarly to previous works.12,16 In addition, the IC50 values
were obtained from heterogeneous sources, and it can be
assumed that the experimental conditions were diverse.
However, we avoided major sources of variability by selecting
IC50 values registered in mammalian ventricular tissues when
available and discarding those extracted from Xenopus oocytes
(as described in the Methods section). We considered that all
published data represents a distribution of values aﬀected by
random error plus variability due to diﬀerences in the
experimental conditions. From this distribution, we picked
the value at the center (the median), as a pragmatic approach to
summarize all these values into a single one. Median is a robust
estimator of the central tendency of a data sample, less sensitive
to the presence of extreme values, and for this reason it was
preferred over the average.
Our method does not include drug eﬀects on Na+ channels,
which is related to the misclassiﬁcation of quetiapine,
ranolazine, and lamotrigine, which can signiﬁcantly block Na+
channels at EFTPC. Future work will include this channel.
In our model, drug−channel interactions are simulated using
the simple pore block model, which may be too simplistic.
Consideration of the Hill coeﬃcient of the sigmoidal curve
ﬁtted to the concentration−current response curves could
provide little beneﬁt, as suggested by other authors.15,16,31
Moreover, drug binding kinetics have not been considered in
this paper although they have been related to increased
susceptibility to acquired long QT syndrome in the presence of
hERG channel kinetic abnormalities.26 Also, our simulations do
not consider other aspects of the compounds, such as
pharmacokinetics/pharmacodynamics, physiology impact, me-
tabolites, or drug−drug interactions. It would have enriched the
results of this study, unfortunately, there is a lack of
experimental data for the inclusion of these phenomena for
all the compounds considered in this study.
In this work, compounds have been classiﬁed using the
clinical human torsadogenic risk classiﬁcation from Credible-
Meds, which feeds from clinical data.31 However, some of the
compounds used in this study are classiﬁed diﬀerently in other
sources, such as amiodarone, clarithromycin, clozapine,
domperidone, donepezil, lapatinib, moxiﬂoxacin, or ranola-
zine.21 Indeed, a large number of compounds with contra-
dicting classiﬁcation have been listed by Wisniowska and
Polak,21 who raise the need of a standardized classiﬁcation for
drug proarrhythmicity risk.
5. CONCLUSIONS
In this study, we introduce a new in silico tool to predict the
eﬀect of a drug on the APD and QT prolongation and its
proarrhythmic risk using the valuable Tx index. It takes into
account both the maximum EFTPC and the multichannel eﬀect
of the drugs. Although there is no doubt about the high
inﬂuence of the hERG block of a drug on the QT prolongation
and the likelihood of TdP, our results highlight the need of
considering the EFTPC and the blocking eﬀects on the
diﬀerent channels of a drug for improving the prediction of
cardiotoxicity, factors that are integrated in the Tx index. This
work contributes to comprehensive in vitro proarrhythmia
assay (CiPA) initiative by using an in silico human model to
obtain a more accurate prediction of human QT and pro-
arrhythmic risk of TdP. Our results show that all these four
tests based on Tx provide very similar predictions and that
good torsadogenic risk predictions can be obtained based on
the endocardial APD prolongation (Tx-APDEndo) of human
isolated cells. This test could be used to predict the human QT
prolongation caused by a compound in the diﬀerent phases of
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drug discovery only using a test concentration and the blocking
potency of the compound to IKr, IKs, and ICaL or even to obtain
an estimate of the maximum safe free plasma concentration that
prevents excessive QT and APD prolongations.
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